Prostate cancer 'fingerprint' detected in blood sample

March 09, 2020

Scientists at UCL have invented a new test to identify the earliest genetic changes of prostate cancer in blood: a process which could allow doctors to see if cancers have spread, monitor tumour behaviour and enable better treatment selection.

In the study, published in The Journal of Clinical Investigation, researchers at UCL Cancer Institute used Next Generation Sequencing (NGS) to establish if they could identify prostate cancer DNA in blood plasma. Previous studies have focused on tissue samples, however this requires an invasive biopsy.

Researchers say their successful discovery in blood represents a prostate tissue "fingerprint", or early circulating biomarker, and when detected identifies that cancer is active and spreading. As this can be detected in a simple blood test, commonly known as a liquid biopsy, physicians could monitor cancer response to treatment regularly and in real-time.

Moving forward researchers will see if this test could complement or replace the existing prostate specific antigen test, which is used for prostate cancer diagnosis and treatment monitoring.

Lead author, Dr Anjui Wu (UCL Cancer Institute), said: "Metastatic prostate cancer - the most dangerous late stage of the disease - can vary substantially in its treatment response and clinical progression.

"We urgently need biomarkers that will help us determine how far along each patient's cancer is, to determine the best course of treatment.

"With tumour biopsies difficult to obtain, being able to identify prostate cancer DNA signatures at the earliest opportunity in blood, will help monitor patients better and assist more effective treatment selection and combination."

In this proof of concept study, the researchers set out to investigate a process called DNA methylation - that is, a chemical change in DNA molecules that can affect gene function and has been studied in tissues.

To do this, the methylation and genome profiles of circulating-cell free DNA (degraded DNA fragments released to the blood plasma) from 25 metastatic prostate cancer patients were concurrently profiled using NGS. As a control, four healthy blood plasma samples were also analysed.

The research group interrogated the molecular profiles to identify circulating tumour DNA (ctDNA) methylations, which can be used to sensitively track tumour content change.

Traditionally, the amount and quality of circulating cell-free DNA extracted from blood can be limited: surprisingly, researchers discovered 1,000s of methylation changes specific to the prostate gland in blood samples from men with prostate cancer. Using this finding, they developed these changes into a signature (a blood test that can be used in the clinic) for tracking prostate genetic material in blood to monitor cancer activity.

Corresponding author, Professor Gert Attard (UCL Cancer Institute), said:

"We are now testing our new technique in trial patients to see if it can complement or substitute the traditional serum prostate specific antigen (PSA) for diagnosis, risk assignment and monitoring how well a treatment is working.

"We believe the increased sensitivity and additional information we derive, will significantly improve the outcomes of men with advanced prostate cancer."

Professor Mark Emberton, Dean of the Faculty of Medical Sciences at UCL, said "The field of liquid biopsies has shown great potential recently to improve the diagnosis and management of cancer patients.

"This test could be the first to tell us cancer has got into blood before the spread is large enough to see on imaging. This could allow targeting of treatment for men at the highest risk of prostate cancer spread."
-end-
Peer reviewed; meta-analysis; people

This research was funded by a Prostate Cancer Foundation Challenge Award, with additional support from Cancer Research UK, and the John Black Charitable Foundation.

University College London

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.